Determination of the solubility, dissolution enthalpy and entropy of DEFLAZACORT (cas 13649-88-2) in different solvents
-
Add time:09/06/2019 Source:sciencedirect.com
The solubility of DEFLAZACORT (cas 13649-88-2) in four solvents, acetone, ethyl acetate, ethanol and 2-propanol, was measured at temperatures ranging from 293.15 K to 348.15 K at atmospheric pressure using Laser Monitoring Technique. The solubility data were correlated by the modified Apelblat model. Then the dissolution enthalpy and entropy of Deflazacort were predicted from the solubility data using van’t Hoff equation. In this study, it should be concluded that the viscosity and surface tension of solvents affect the solubility behavior, dissolution enthalpy and entropy of Deflazacort in different solvents.
We also recommend Trading Suppliers and Manufacturers of DEFLAZACORT (cas 13649-88-2). Pls Click Website Link as below: cas 13649-88-2 suppliers
Prev:Clinical ObservationsThe Impact of DEFLAZACORT (cas 13649-88-2) on Puberty in Duchenne Muscular Dystrophy
Next:DEFLAZACORT (cas 13649-88-2)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Case reportTwo siblings with limb-girdle muscular dystrophy type 2E responsive to DEFLAZACORT (cas 13649-88-2)09/26/2019
- Case ReportToxic epidermal necrolysis associated with DEFLAZACORT (cas 13649-88-2) therapy with nephrotic syndrome09/25/2019
- A comparative study of hydrocortisone versus DEFLAZACORT (cas 13649-88-2) in drug-resistant epilepsy of childhood09/24/2019
- Identification of plasma interleukins as biomarkers for DEFLAZACORT (cas 13649-88-2) and omega-3 based Duchenne muscular dystrophy therapy09/10/2019
- Original ArticleDEFLAZACORT (cas 13649-88-2) alleviate pro-inflammatory cytokines expression, oxidative stress and histopathological alterations in collagen induced arthritis in Wistar rats09/09/2019
- Short communicationIsolation and structural characterization of novel photolytic degradation impurities of DEFLAZACORT (cas 13649-88-2) using Q-TOF, 2D-NMR and FTIR09/08/2019
- DEFLAZACORT (cas 13649-88-2)09/07/2019
- Clinical ObservationsThe Impact of DEFLAZACORT (cas 13649-88-2) on Puberty in Duchenne Muscular Dystrophy09/05/2019